(Q36380878)

13 August 2017

1 reference

title

Carcinoid syndrome: diagnosis and medical management (English)

1 reference

13 August 2017

1 reference

2

Wouter W de Herder

1 reference

13 August 2017

1

Aart J van der Lely

1 reference

13 August 2017

publication date

1 October 2005

1 reference

Arquivos Brasileiros de Endocrinologia e Metabologia

13 August 2017

published in

1 reference

13 August 2017

volume

49

1 reference

13 August 2017

issue

5

1 reference

13 August 2017

page(s)

850-860

1 reference

Highlights of the biology of endocrine tumours of the gut and pancreas.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Current status of gastrointestinal carcinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Complications of midgut carcinoid tumors and carcinoid syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Daily cyclic changes in the urinary excretion of 5-hydroxyindoleacetic acid in patients with carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Somatostatin receptor scintigraphy in patients with carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Intraoperative tumour detection using 111In-DTPA-D-Phe1-octreotide and a scintillation detector

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Developments in PET for the detection of endocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Ileal carcinoid tumor as a cause of massive lower-GI bleeding: the role of capsule endoscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Interventional treatment of the carcinoid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Diagnostic, surgical and medical aspect of the midgut carcinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Management of midgut carcinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Radioembolization for hepatic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Chemotherapy in the treatment of neuroendocrine malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Somatostatin analogue treatment of neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Somatostatin and somatostatin analogues: diagnostic and therapeutic uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Somatostatin Analog Therapy in Treatment of Gastrointestinal Disorders and Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Medical treatment of metastasizing carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Adding interferon-α to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Interferon in the management of neuroendocrine GEP-tumors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

The diagnosis and medical management of advanced neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

New somatostatin analogs: will they fulfil old promises?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

The pathophysiological consequences of somatostatin receptor internalization and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

Peptide receptors as molecular targets for cancer diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302005000500028

10.1590/S0004-27302005000500028

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference